The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma
Abstract
Virtually no progress has been made during more than 2 decades of clinical trials for multiple myeloma (MM) involving standard therapy (ST). Recent studies suggest that dose intensification requiring hematopoietic stem cell support results in higher complete response (CR) rates and extended disease control. “Total Therapy” (TT) consisting of non–cross-resistant induction regimens, followed by a double autotransplant (AT) procedure, was administered to 123 untreated patients with symptomatic MM. Upon hematologic recovery, interferon (IFN) maintenance (3 million units [MU]/m2 subcutaneously thrice weekly) was given until disease recurrence/progression. Results were compared with the outcome of untreated patients receiving ST according to Southwest Oncology Group (SWOG) trials. One hundred sixteen pair mates were selected from both TT and among 1,123 patients to match for the major prognostic features. TT induced CR in 40% of all 123 patients (intent-to-treat). By 12 months, 7% had died, including 4% from treatment-related complications. With a median follow-up of 31 months, median durations of event-free survival (EFS) and overall survival (OS) are 49 and 62+ months, respectively. Abnormalities of chromosomes 11q and 13 were associated with inferior outcome, whereas CR within 6 months after induction was a favorable prognostic feature for both EFS and OS. In comparison to ST, TT induced higher PR rates (85% v 52%, P < .0001) (CR rates not available on SWOG trials) and extended EFS (49 v 22 months, P = .0001) and OS (62+ v 48 months, P = .01). Compared to ST, dose intensification with double AT markedly augments tumor cytoreduction, effecting not only higher CR rates but also significantly extending EFS and OS in previously untreated patients with MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gianni, A., Bregni, M., Stern, A., Siena, S., Tarella, C., Pileri, A., & Bonadonna, G. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90711-3 · Cited by 740
Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents
Barlogie, B., Smith, L., & Alexanian, R. (1984) · New England Journal of Medicine · doi:10.1056/nejm198405243102104 · Cited by 641
Self-citationGraft-versus-myeloma effect: proof of principle
Tricot, G., Vesole, D., Jagannath, S., Hilton, J., Munshi, N., & Barlogie, B. (1996) · Blood · doi:10.1182/blood.v87.3.1196.bloodjournal8731196 · Cited by 543
Self-citationHIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA
MCELWAIN, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90739-0 · Cited by 510
Tricot, G., Barlogie, B., Jagannath, S., Bracy, D., Mattox, S., Vesole, D., Naucke, S., & Sawyer, Jr. (1995) · Blood · doi:10.1182/blood.v86.11.4250.bloodjournal86114250 · Cited by 395
Self-citationPrognostic factors in allogeneic bone marrow transplantation for multiple myeloma.
Gahrton, G., Tura, S., Ljungman, P., Bladé, J., Brandt, L., Cavo, M., Façon, T., Gratwohl, A., Hagenbeek, A., & Jacobs, P. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1312 · Cited by 285
Multiple myeloma: significance of plasmablastic subtype in morphological classification
Greipp, P., Raymond, N., Kyle, R., & O'Fallon, W. (1985) · Blood · doi:10.1182/blood.v65.2.305.305 · Cited by 263
Salmon, S. E., Crowley, J. J., Grogan, T. M., Finley, P. R., Pugh, R. P., & Barlogie, B. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2405 · Cited by 132
Self-citationWestin, J., Rödjer, S., Turesson, I., Cortelezzi, A., Hjorth, M., Zador, G., & for a Cooperative Study Group (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb08364.x · Cited by 92
Salmon, S. E., Tesh, D. W., Crowley, J. J., Saeed, S. M., Finley, P. R., Milder, M. S., Hutchins, L. F., Coltman, C. A., Bonnet, J. D., & Cheson, B. D. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1575 · Cited by 58
Self-citation
Cited by
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Self-citationRaje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Self-citation
Metadata
- Authors
- Barlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., & Tricot, G.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1997-02-01
- Volume
- 89
- Issue
- 3
- Pages
- 789-793
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W20342555
- Cited by
- 541
- References
- 10
- FWCI
- 19.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma. https://app.cochat.ai/papers/10.1182/blood.v89.3.789
- The paper
- Barlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., & Tricot, G. (1997). Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma. Blood. https://doi.org/10.1182/blood.v89.3.789
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.